Browsing by Author "Altindis M."

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    The effect of zinc supplementation in experimentally induced Toxoplasma gondii infection.
    (1995) Tasçi S.; Sengil A.Z.; Altindis M.; Arisoy K.
    The effect of zinc added diet on cellular immunity in toxoplasmosis was investigated on 50 male wistar albino rats. Total lymphocyte CB8 count were found higher in the infected group when compared to the control group (P < 0.001). The relative increase of CD8 was found to be responsible for the decrease in ratio. In the infected group, there was a slight decrease in CD4 count but it was statistically insignificant. While no significant differences in serum zinc level were observed between the groups, there was a positive correlation with CD8 count in infected group (r = 0.005, P < 0.05). As a result, zinc added diet in toxoplasmosis stimulated the cellular immunity, increased CD8 and total lymphocytes.
  • No Thumbnail Available
    Item
    Comparison of immunogenicity for Sinovac-CoronaVac vaccine vs. natural infection during cancer treatment
    (Verduci Editore s.r.l, 2023) Çakir E.; Saydan D.; Gülbagci B.; Özen M.; Uǧurlu İ.; Demirci A.; Bilir F.; Hacibekiroglu İ.; Yildiz N.; Akcali S.; Altindis M.; Varim C.; Yaylaci S.; Bilir C.
    OBJECTIVE: Efficacy of the COVID-19 vaccines in cancer patients, especially during their active treatment, are lacking. Most of the studies in the literature compared the immunity in cancer patients with a cross-sectional cohort or retrospectively. Our study investigated Sinovac- CoronaVac COVID-19 vaccine immunogenicity and compared it with natural COVID-19 disease in cancer patients during their cancer therapy. PATIENTS AND METHODS: A total of 111 patients with cancer and who are on active treatment were included in the study. This is a single- center study and was designed prospectively. Two group of patients were included in the study, natural disease and vaccinated group. RESULTS: A total of 111 patients were included in the study, 34 of whom had natural COVID-19 disease. Antibody levels following the first dose vaccine were 0.4 (0-1.9) U/ml while after the second dose of vaccine were 2.6 (1.0- 7.25) U/ml. Immunogenicity levels were 82.4% in the natural disease group and 75.8% in the vaccinated group after the second shot of the vaccine. Immunogenicity rate was significantly higher in non-chemotherapy (receiving immunotehrapy/ targeted therapy or biologic agent) group compared to chemotherapy drug (92.9% vs. 63.3%, p=0.004). There was a difference between the antibody levels following the first and second vaccination [median (IQR): 0.3 (0-1.0) and 3.3 (2.0-6.7), p=0.001, respectively]. CONCLUSIONS: The present study revealed that the Sinovac-CoronaVac vaccine showed an acceptable immunogenicity following two shots in cancer patients who were receiving active systemic therapy. On the other hand, natural disease immunogenicity was higher than vaccinated group. © 2023 Verduci Editore s.r.l. All rights reserved.